APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Asthma and COPD

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Asthma and COPD Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchDrugs for Asthma and COPD Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Asthma and COPD Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Drugs for Asthma and COPD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Asthma and COPD Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Asthma and COPD Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Drugs for Asthma and COPD market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for Asthma and COPD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Asthma and COPD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Asthma and COPD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for Asthma and COPD market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for Asthma and COPD market include GSK, Teva, Novartis, Merck, Mylan, Roche, AstraZeneca, Vertex and Sumitomo Dainippon, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drugs for Asthma and COPD market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Asthma and COPD and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Asthma and COPD revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drugs for Asthma and COPD market.

Drugs for Asthma and COPD Segment by Company

GSK

Teva

Novartis

Merck

Mylan

Roche

AstraZeneca

Vertex

Sumitomo Dainippon

Chiesi

Boehringer Ingelheim

Beximco

Drugs for Asthma and COPD Segment by Type

Inhalable & Nasal Spray

Oral

Others

Drugs for Asthma and COPD Segment by Application

Asthma

COPD

Drugs for Asthma and COPD Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Asthma and COPD status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drugs for Asthma and COPD key companies, revenue, market share, and recent developments.

3. To split the Drugs for Asthma and COPD breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drugs for Asthma and COPD market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Asthma and COPD significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Asthma and COPD competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Asthma and COPD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Asthma and COPD and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Asthma and COPD.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Asthma and COPD industry.

Chapter 3: Detailed analysis of Drugs for Asthma and COPD company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drugs for Asthma and COPD in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drugs for Asthma and COPD in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Asthma and COPD Industry Trends Table 2. Drugs for Asthma and COPD Industry Drivers Table 3. Drugs for Asthma and COPD Industry Opportunities and Challenges Table 4. Drugs for Asthma and COPD Industry Restraints Table 5. Global Drugs for Asthma and COPD Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Asthma and COPD Revenue Share by Company (2021-2026) Table 7. Global Drugs for Asthma and COPD Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drugs for Asthma and COPD Key Company Manufacturing Base & Headquarters Table 9. Global Drugs for Asthma and COPD Company, Product Type & Application Table 10. Global Drugs for Asthma and COPD Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drugs for Asthma and COPD by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Inhalable & Nasal Spray Table 15. Significant Companies of Oral Table 16. Significant Companies of Others Table 17. Global Drugs for Asthma and COPD Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Drugs for Asthma and COPD Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Drugs for Asthma and COPD Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Drugs for Asthma and COPD Sales Value Share by Type (2021-2026) Table 21. Global Drugs for Asthma and COPD Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Asthma Table 23. Significant Companies of COPD Table 24. Global Drugs for Asthma and COPD Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Drugs for Asthma and COPD Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Drugs for Asthma and COPD Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Drugs for Asthma and COPD Sales Value Share by Application (2021-2026) Table 28. Global Drugs for Asthma and COPD Sales Value Share by Application (2027-2032) Table 29. Global Drugs for Asthma and COPD Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Drugs for Asthma and COPD Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Drugs for Asthma and COPD Sales Value Share by Region (2021-2026) Table 32. Global Drugs for Asthma and COPD Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Drugs for Asthma and COPD Sales Value Share by Region (2027-2032) Table 34. Global Drugs for Asthma and COPD Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Drugs for Asthma and COPD Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Drugs for Asthma and COPD Sales Value Market Share by Country (2021-2026) Table 37. Global Drugs for Asthma and COPD Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Drugs for Asthma and COPD Sales Value Market Share by Country (2027-2032) Table 39. GSK Company Information Table 40. GSK Business Overview Table 41. GSK Drugs for Asthma and COPD Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. GSK Drugs for Asthma and COPD Product Portfolio Table 43. GSK Recent Development Table 44. Teva Company Information Table 45. Teva Business Overview Table 46. Teva Drugs for Asthma and COPD Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Teva Drugs for Asthma and COPD Product Portfolio Table 48. Teva Recent Development Table 49. Novartis Company Information Table 50. Novartis Business Overview Table 51. Novartis Drugs for Asthma and COPD Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Novartis Drugs for Asthma and COPD Product Portfolio Table 53. Novartis Recent Development Table 54. Merck Company Information Table 55. Merck Business Overview Table 56. Merck Drugs for Asthma and COPD Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Merck Drugs for Asthma and COPD Product Portfolio Table 58. Merck Recent Development Table 59. Mylan Company Information Table 60. Mylan Business Overview Table 61. Mylan Drugs for Asthma and COPD Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Mylan Drugs for Asthma and COPD Product Portfolio Table 63. Mylan Recent Development Table 64. Roche Company Information Table 65. Roche Business Overview Table 66. Roche Drugs for Asthma and COPD Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Roche Drugs for Asthma and COPD Product Portfolio Table 68. Roche Recent Development Table 69. AstraZeneca Company Information Table 70. AstraZeneca Business Overview Table 71. AstraZeneca Drugs for Asthma and COPD Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. AstraZeneca Drugs for Asthma and COPD Product Portfolio Table 73. AstraZeneca Recent Development Table 74. Vertex Company Information Table 75. Vertex Business Overview Table 76. Vertex Drugs for Asthma and COPD Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Vertex Drugs for Asthma and COPD Product Portfolio Table 78. Vertex Recent Development Table 79. Sumitomo Dainippon Company Information Table 80. Sumitomo Dainippon Business Overview Table 81. Sumitomo Dainippon Drugs for Asthma and COPD Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Sumitomo Dainippon Drugs for Asthma and COPD Product Portfolio Table 83. Sumitomo Dainippon Recent Development Table 84. Chiesi Company Information Table 85. Chiesi Business Overview Table 86. Chiesi Drugs for Asthma and COPD Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Chiesi Drugs for Asthma and COPD Product Portfolio Table 88. Chiesi Recent Development Table 89. Boehringer Ingelheim Company Information Table 90. Boehringer Ingelheim Business Overview Table 91. Boehringer Ingelheim Drugs for Asthma and COPD Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Boehringer Ingelheim Drugs for Asthma and COPD Product Portfolio Table 93. Boehringer Ingelheim Recent Development Table 94. Beximco Company Information Table 95. Beximco Business Overview Table 96. Beximco Drugs for Asthma and COPD Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Beximco Drugs for Asthma and COPD Product Portfolio Table 98. Beximco Recent Development Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Drugs for Asthma and COPD Product Image Figure 2. Global Drugs for Asthma and COPD Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Asthma and COPD Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Asthma and COPD Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Inhalable & Nasal Spray Image Figure 8. Oral Image Figure 9. Others Image Figure 10. Global Drugs for Asthma and COPD Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Drugs for Asthma and COPD Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Drugs for Asthma and COPD Sales Value Share by Type (2021-2032) Figure 13. Asthma Image Figure 14. COPD Image Figure 15. Global Drugs for Asthma and COPD Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Drugs for Asthma and COPD Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Drugs for Asthma and COPD Sales Value Share by Application (2021-2032) Figure 18. Global Drugs for Asthma and COPD Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Drugs for Asthma and COPD Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Drugs for Asthma and COPD Sales Value (2021-2032) & (US$ Million) Figure 21. North America Drugs for Asthma and COPD Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Drugs for Asthma and COPD Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Drugs for Asthma and COPD Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Drugs for Asthma and COPD Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Drugs for Asthma and COPD Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Drugs for Asthma and COPD Sales Value (2021-2032) & (US$ Million) Figure 27. South America Drugs for Asthma and COPD Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Drugs for Asthma and COPD Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Drugs for Asthma and COPD Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Inhalable & Nasal Spray
  • Oral
  • Others
Applications
  • Asthma
  • COPD
Companies covered
  • GSK
  • Teva
  • Novartis
  • Merck
  • Mylan
  • Roche
  • AstraZeneca
  • Vertex
  • Sumitomo Dainippon
  • Chiesi
  • Boehringer Ingelheim
  • Beximco

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Asthma and COPD Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Asthma and COPD Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drugs for Asthma and COPD Market Dynamics
  1. 2.1 Drugs for Asthma and COPD Industry Trends
  2. 2.2 Drugs for Asthma and COPD Industry Drivers
  3. 2.3 Drugs for Asthma and COPD Industry Opportunities and Challenges
  4. 2.4 Drugs for Asthma and COPD Industry Restraints
3 Drugs for Asthma and COPD Market by Company
  1. 3.1 Global Drugs for Asthma and COPD Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Asthma and COPD Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Asthma and COPD Company Ranking (2024-2026)
  4. 3.4 Global Drugs for Asthma and COPD Company Manufacturing Base and Headquarters
  5. 3.5 Global Drugs for Asthma and COPD Company Product Type and Application
  6. 3.6 Global Drugs for Asthma and COPD Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drugs for Asthma and COPD Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drugs for Asthma and COPD Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drugs for Asthma and COPD Market by Type
  1. 4.1 Drugs for Asthma and COPD Type Introduction
  2. 4.1.1 Inhalable & Nasal Spray
  3. 4.1.2 Oral
  4. 4.1.3 Others
  5. 4.2 Global Drugs for Asthma and COPD Sales Value by Type
  6. 4.2.1 Global Drugs for Asthma and COPD Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs for Asthma and COPD Sales Value by Type (2021-2032)
  8. 4.2.3 Global Drugs for Asthma and COPD Sales Value Share by Type (2021-2032)
5 Drugs for Asthma and COPD Market by Application
  1. 5.1 Drugs for Asthma and COPD Application Introduction
  2. 5.1.1 Asthma
  3. 5.1.2 COPD
  4. 5.2 Global Drugs for Asthma and COPD Sales Value by Application
  5. 5.2.1 Global Drugs for Asthma and COPD Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Drugs for Asthma and COPD Sales Value by Application (2021-2032)
  7. 5.2.3 Global Drugs for Asthma and COPD Sales Value Share by Application (2021-2032)
6 Drugs for Asthma and COPD Regional Value Analysis
  1. 6.1 Global Drugs for Asthma and COPD Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Asthma and COPD Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drugs for Asthma and COPD Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drugs for Asthma and COPD Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Asthma and COPD Sales Value (2021-2032)
  7. 6.3.2 North America Drugs for Asthma and COPD Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drugs for Asthma and COPD Sales Value (2021-2032)
  10. 6.4.2 Europe Drugs for Asthma and COPD Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drugs for Asthma and COPD Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drugs for Asthma and COPD Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drugs for Asthma and COPD Sales Value (2021-2032)
  16. 6.6.2 South America Drugs for Asthma and COPD Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drugs for Asthma and COPD Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drugs for Asthma and COPD Sales Value Share by Country, 2025 VS 2032
7 Drugs for Asthma and COPD Country-level Value Analysis
  1. 7.1 Global Drugs for Asthma and COPD Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Asthma and COPD Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drugs for Asthma and COPD Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drugs for Asthma and COPD Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drugs for Asthma and COPD Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drugs for Asthma and COPD Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drugs for Asthma and COPD Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Drugs for Asthma and COPD Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Drugs for Asthma and COPD Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Drugs for Asthma and COPD Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Drugs for Asthma and COPD Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Drugs for Asthma and COPD Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Drugs for Asthma and COPD Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Drugs for Asthma and COPD Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Vertex
  44. 8.8.1 Vertex Company Information
  45. 8.8.2 Vertex Business Overview
  46. 8.8.3 Vertex Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Vertex Drugs for Asthma and COPD Product Portfolio
  48. 8.8.5 Vertex Recent Developments
  49. 8.9 Sumitomo Dainippon
  50. 8.9.1 Sumitomo Dainippon Company Information
  51. 8.9.2 Sumitomo Dainippon Business Overview
  52. 8.9.3 Sumitomo Dainippon Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sumitomo Dainippon Drugs for Asthma and COPD Product Portfolio
  54. 8.9.5 Sumitomo Dainippon Recent Developments
  55. 8.10 Chiesi
  56. 8.10.1 Chiesi Company Information
  57. 8.10.2 Chiesi Business Overview
  58. 8.10.3 Chiesi Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Chiesi Drugs for Asthma and COPD Product Portfolio
  60. 8.10.5 Chiesi Recent Developments
  61. 8.11 Boehringer Ingelheim
  62. 8.11.1 Boehringer Ingelheim Company Information
  63. 8.11.2 Boehringer Ingelheim Business Overview
  64. 8.11.3 Boehringer Ingelheim Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim Drugs for Asthma and COPD Product Portfolio
  66. 8.11.5 Boehringer Ingelheim Recent Developments
  67. 8.12 Beximco
  68. 8.12.1 Beximco Company Information
  69. 8.12.2 Beximco Business Overview
  70. 8.12.3 Beximco Drugs for Asthma and COPD Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Beximco Drugs for Asthma and COPD Product Portfolio
  72. 8.12.5 Beximco Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst